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testing. As they point out, routinely used molecular 
assays for HEV diagnostics or blood donor screening 
would not be able to detect HEV-C1.(3) Although 
we demonstrated that the Wantai HEV immu-
noglobulin M (IgM) and immunoglobulin G kits 
(Wantai, Beijing, China) may cross-react with the 
sera of patients with HEV-C1,(1) HEV-A/HEV-C1 
discriminatory assays would be a valuable asset to 
HEV diagnostics.
For 40 of the HEV IgM-positive/RNA-negative 
patients with sufficient sample volume, we also 
attempted conventional RT-PCR using universal con-
sensus primers as described previously.(3) These primers 
would theoretically be able to detect highly divergent 
species within the family Hepeviridae, but all samples 
tested negative. As noted in our study, our real-time 
PCR primers and probes were specific for HEV-C gen-
otype 1, which circulates in rats.(1) However, HEV-C is 
very diverse, with four putative genotypes circulating in 
a variety of rodents and ferrets.(4) Our HEV-C1 real-
time PCR would not detect HEV-C genotypes 3 and 
4, which circulate in field mice and voles.(4) However, 
we judge that urban dwellers in Hong Kong are less 
likely to be exposed to these genotypes.
The route of transmission of HEV-C1 between 
rats and humans is elusive. None of our patients had 
a history of rat meat consumption, and the practice is 
uncommon in Hong Kong. Indeed, almost all of them 
even denied rat infestation in their domestic prem-
ises. We considered adulteration of food products or 
natural HEV-C1 infection of pigs to be possibilities, 
so we tested for HEV-C1 in 212 pork products and 
samples. However, none of the samples tested posi-
tive.(1) We agree that extensive epidemiological inves-
tigations are required to identify the definitive source 
of HEV-C1 infection.
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Letter to the Editor: Does Augmenter of Liver Regeneration 
Deficiency Pave the Way for Nonalcoholic Steatohepatitis 
Progression?
TO THE EDITOR:
We read with interest the recent article by Kumar 
et al.(1) on the impact of augmenter of liver regeneration 
(ALR) deficiency on nonalcoholic fatty liver disease 
(NAFLD) progression from steatosis to nonalco-
holic steatohepatitis (NASH). By using hepatocyte- 
specific ALR knockout/knockdown high-fat/high- 
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carbohydrate mouse models, they demonstrated an 
involvement of ALR in lipid metabolism, oxidative 
stress, and inflammatory response leading to fibro-
sis. However, ALR is expressed in three isoforms 
(15, 21, 23 kDa),(2) and their specific roles in this 
“loss-of-function” strategy is not addressed. In ear-
lier publications, using an overexpression approach 
(“gain-of-function”) of the mainly mitochondrial 
23-kDa ALR, a reduction in hepatic fibrosis and 
ischemia reperfusion injury (IRI) in steatotic livers 
was shown.(2) Expression of cytosolic 15-kDa ALR 
reduced severity of liver injury in a methionine-cho-
line–deficient NASH mouse model.(2) Furthermore, it 
was shown that cytosolic 15-kDa ALR, different from 
exogenously applied 15-kDa ALR, diminished triacyl-
glycerol levels and lipoapotosis in vitro by attenuating 
endoplasmatic stress, increasing lipolytic and decreas-
ing lipogenic gene expression.(3) Additionally, treat-
ment with exogenous ALR reduced hepatic IRI in 
mice by reducing neutrophil infiltration through less 
hepatocytic chemokine expression.(4) More detailed 
knowledge of the function of individual ALR iso-
forms is necessary for future therapeutic interventions.
Kumar et al. found decreased ALR levels in human 
NASH patients (tissue and serum) and pointed to a 
lack of information about ALR regulation. This was 
addressed earlier, demonstrating reduced hepatic ALR 
mRNA levels in patients with steatosis and even more 
with NASH.(2,3) ALR is regulated, among others, by 
forkhead box A2 (FOXA2; hepatocyte nuclear fac-
tor 3β), which translocates from the nucleus to the 
cytosol upon treatment with free fatty acids, and 
whose expression correlates with ALR expression 
in NAFLD patients.(3) Nuclear factor erythroid 2–
related factor 2 (Nrf2), another ALR-regulating 
transcription factor,(2) was shown to attenuate liver 
steatosis and therefore it is likely that FOXA2 and 
Nrf2 diminished endogenous ALR levels in hepatic 
steatosis/NASH. However, the conclusion that ALR 
deficiency may be a major determinant of accelerated 
progression of NASH to end-stage liver disease, that 
is, cirrhosis, is not supported by enhanced ALR levels 
in patients with cirrhosis(2) or by clinical characteriza-
tion of patients with mutations in the growth factor 
erv1-like (GFER) gene (encoding for ALR) showing 
almost no distinctive feature regarding hepatic func-
tion(2) and therefore should to be taken with caution.
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Reply:
We appreciate the important points raised by Weiss 
et al.(1) Our data indicate that the loss of 21/23 kDa 
Augmenter of liver regeneration (ALR), in mice and 
humans, renders the liver compromised to develop 
NASH.(2) Administration of 21/23  kDa ALR to 
hepatocyte-specific ALR-knockout (ALR-H-KO) 
mice between 1 and 2  weeks postpartum mitigated 
steatohepatitis.(3) The 15  kDa ALR is absent (Fig. 
8)(2)(Ref. 71 in (4)) or expressed at a very low level(5) in 
human liver and absent in mouse liver.(2,4,6) However, 
further investigation of ALR isoform(s) that can be of 
therapeutic intervention is important.
Hepatic ALR is down-regulated in steatosis 
regardless of its etiology in wild-type (WT) mice, 
